<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39403561</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2590-1362</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Vaccine: X</Title><ISOAbbreviation>Vaccine X</ISOAbbreviation></Journal><ArticleTitle>Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adults.</ArticleTitle><Pagination><StartPage>100564</StartPage><MedlinePgn>100564</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100564</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvacx.2024.100564</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Booster COVID-19 vaccinations are used to protect the elderly, a group vulnerable to severe disease. We compared humoral and cellular immunity in older versus younger adults up to eight months after administering a BNT16b2 booster vaccine dose. Next, we analyzed the plasma levels of soluble T cell activation/exhaustion markers.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Home-dwelling older adults (n = 68, median age 86) and younger healthcare workers (n = 35, median age 39), previously vaccinated with two doses of BNT162b2, were given a booster dose at ten months after the initial dose. Our analysis consisted of spike-specific IgG, neutralizing antibodies, memory B cells, IFN-γ and IL-2 secreting T cells and soluble T cell exhaustion/activation markers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Following the initial two doses, the elderly cohort exhibited lower humoral and IFN-γ responses compared to younger adults. The booster dose increased the humoral responses in both older and younger adults. At two months after the booster dose, older and younger vaccinees had comparable levels of antibodies and the responses were maintained up to 18 months. The younger cohort elicited an increase in the cellular response, while no increase was detected in the elderly. The elderly had higher plasma levels of soluble forms of the T cell activation/exhaustion markers CD25 and TIM-3, which inversely correlated with age and T-cell cytokine responses. This suggests that these markers may be related to the observed dysfunctional cellular cytokine response in older adults. However, both elderly and younger adults who experienced breakthrough infections after booster vaccination, elicited more robust humoral and IFN-γ responses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The booster dose elicited neutralizing and spike-specific antibody responses in the elderly that were comparable with that of the younger cohort. However, the lack of a strong cellular cytokine response to the third dose in the elderly may explain their vulnerability to severe infection and may be a consequence of exhausted or senescent T cell responses. (https://clinicaltrials.gov/study/NCT04706390).</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bredholt</LastName><ForeName>Geir</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sævik</LastName><ForeName>Marianne</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Søyland</LastName><ForeName>Hanne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medicine, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueland</LastName><ForeName>Thor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pathirana</LastName><ForeName>Rishi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madsen</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vahokoski</LastName><ForeName>Juha</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lartey</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halvorsen</LastName><ForeName>Bente E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahl</LastName><ForeName>Tuva B</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trieu</LastName><ForeName>Mai-Chi</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohn</LastName><ForeName>Kristin G-I</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brokstad</LastName><ForeName>Karl Albert</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Safety, Chemistry and Biomedical Laboratory Sciences, Western Norway University of Applied Sciences, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aukrust</LastName><ForeName>Pål</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tøndel</LastName><ForeName>Camilla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langeland</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Centre for Tropical Infectious Diseases, Department of Medicine, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blomberg</LastName><ForeName>Bjørn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Centre for Tropical Infectious Diseases, Department of Medicine, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Rebecca Jane</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Bergen COVID-19 Research Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04706390</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Vaccine X</MedlineTA><NlmUniqueID>101748769</NlmUniqueID><ISSNLinking>2590-1362</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aging</Keyword><Keyword MajorTopicYN="N">Interferon-gamma</Keyword><Keyword MajorTopicYN="N">Memory B cells</Keyword><Keyword MajorTopicYN="N">Neutralizing antibodies</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">T-lymphocytes</Keyword><Keyword MajorTopicYN="N">mRNA vaccines</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39403561</ArticleId><ArticleId IdType="pmc">PMC11472110</ArticleId><ArticleId IdType="doi">10.1016/j.jvacx.2024.100564</ArticleId><ArticleId IdType="pii">S2590-1362(24)00137-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Asamoah-Boaheng M., Goldfarb D., Prusinkiewicz M.A., Golding L., Karim M.E., Barakauskas V., et al. Determining the Optimal SARS-CoV-2 mRNA Vaccine Dosing Interval for Maximum Immunogenicity. Cureus. 2023;15(1):e34465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9981229</ArticleId><ArticleId IdType="pubmed">36874687</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusinkiewicz M.A., Sediqi S., Li Y.J., Goldfarb D.M., Asamoah-Boaheng M., Wall N., et al. Effect of vaccine dosing intervals on Omicron surrogate neutralization after three doses of BNT162b2. Heliyon. 2023;9(6):e17259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10263225</ArticleId><ArticleId IdType="pubmed">37332982</ArticleId></ArticleIdList></Reference><Reference><Citation>Naaber P., Tserel L., Kangro K., Sepp E., Jurjenson V., Adamson A., et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8418937</ArticleId><ArticleId IdType="pubmed">34514454</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin D.R., Higdon M.M., Abu-Raddad L.J., Andrews N., Araos R., Goldberg Y., et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924–944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Atmar R.L., Lyke K.E., Deming M.E., Jackson L.A., Branche A.R., El Sahly H.M., et al. Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022;386(11):1046–1057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8820244</ArticleId><ArticleId IdType="pubmed">35081293</ArticleId></ArticleIdList></Reference><Reference><Citation>Naaber P., Tserel L., Kangro K., Punapart M., Sepp E., Jurjenson V., et al. Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine. Cell Rep Med. 2022;3(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9350667</ArticleId><ArticleId IdType="pubmed">35952669</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier D.A., Ferreira I., Kotagiri P., Datir R.P., Lim E.Y., Touizer E., et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596(7872):417–422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373615</ArticleId><ArticleId IdType="pubmed">34192737</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N., Tessier E., Stowe J., Gower C., Kirsebom F., Simmons R., et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. N Engl J Med. 2022;386(4):340–350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8781262</ArticleId><ArticleId IdType="pubmed">35021002</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios-Pedrero M.A., Jansen J.M., Blume C., Stanislawski N., Jonczyk R., Molle A., et al. Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults. Nat Aging. 2022;2(10):896–905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10154205</ArticleId><ArticleId IdType="pubmed">37118289</ArticleId></ArticleIdList></Reference><Reference><Citation>Dallan B., Proietto D., De Laurentis M., Gallerani E., Martino M., Ghisellini S., et al. Age differentially impacts adaptive immune responses induced by adenoviral versus mRNA vaccines against COVID-19. Nat Aging. 2024;4(8):1121–1136.</Citation><ArticleIdList><ArticleId IdType="pubmed">38918602</ArticleId></ArticleIdList></Reference><Reference><Citation>Crooke S.N., Ovsyannikova I.G., Poland G.A., Kennedy R.B. Immunosenescence and human vaccine immune responses. Immun Ageing. 2019;16:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6743147</ArticleId><ArticleId IdType="pubmed">31528180</ArticleId></ArticleIdList></Reference><Reference><Citation>Renia L., Goh Y.S., Rouers A., Le Bert N., Chia W.N., Chavatte J.M., et al. Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. Nat Commun. 2022;13(1):4615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9358634</ArticleId><ArticleId IdType="pubmed">35941158</ArticleId></ArticleIdList></Reference><Reference><Citation>Datwani S., Kalikawe R., Mwimanzi F., Speckmaier S., Liang R., Sang Y., et al. Dynamics of T-cell Responses Following COVID-19 mRNA Vaccination and Breakthrough Infection in Older Adults. Pathog Immun. 2023;8(1):117–135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10686373</ArticleId><ArticleId IdType="pubmed">38035132</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh Y.S., Rouers A., Fong S.W., Zhuo N.Z., Hor P.X., Loh C.Y., et al. Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals. Front Immunol. 2022;13:1031852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9704817</ArticleId><ArticleId IdType="pubmed">36451833</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen L., Brokstad K.A., Bansal A., Zhou F., Bredholt G., Onyango T.B., et al. Durable immune responses after BNT162b2 vaccination in home-dwelling old adults. Vaccine X. 2023;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9830931</ArticleId><ArticleId IdType="pubmed">36643855</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett K.S., Edwards D.K., Leist S.R., Abiona O.M., Boyoglu-Barnum S., Gillespie R.A., et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567–571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7581537</ArticleId><ArticleId IdType="pubmed">32756549</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel A.B., Kanevsky I., Che Y., Swanson K.A., Muik A., Vormehr M., et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021;592(7853):283–289.</Citation><ArticleIdList><ArticleId IdType="pubmed">33524990</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., More K.R., Ojha A., Jackson C.B., Quinlan B.D., Li H., et al. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. npj Vaccines. 2023;8(1):156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10567765</ArticleId><ArticleId IdType="pubmed">37821446</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanat F., Stadlbauer D., Strohmeier S., Nguyen T.H.O., Chromikova V., McMahon M., et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26(7):1033–1036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8183627</ArticleId><ArticleId IdType="pubmed">32398876</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohn K.G., Bredholt G., Zhou F., Madsen A., Onyango T.B., Fjelltveit E.B., et al. Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients. PLoS One. 2022;17(2):e0261979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863217</ArticleId><ArticleId IdType="pubmed">35192617</ArticleId></ArticleIdList></Reference><Reference><Citation>Trieu M.C., Bansal A., Madsen A., Zhou F., Saevik M., Vahokoski J., et al. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study. J Infect Dis. 2021;223(4):589–599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7798943</ArticleId><ArticleId IdType="pubmed">33247924</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagne M., Corbett K.S., Flynn B.J., Foulds K.E., Wagner D.A., Andrew S.F., et al. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. Cell. 2022;185(1):113–30 e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8639396</ArticleId><ArticleId IdType="pubmed">34921774</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber T, Dahling S, Rose S, Affeldt P, Vanshylla K, Ullrich L, et al. Enhanced SARS-CoV-2 humoral immunity following breakthrough infection builds upon the preexisting memory B cell pool. Sci Immunol. 2023;8(89):eadk5845.</Citation><ArticleIdList><ArticleId IdType="pubmed">37976348</ArticleId></ArticleIdList></Reference><Reference><Citation>Muecksch F., Wang Z., Cho A., Gaebler C., Ben Tanfous T., DaSilva J., et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature. 2022;607(7917):128–134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9259484</ArticleId><ArticleId IdType="pubmed">35447027</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruhn M., Obara M., Chiyyeadu A., Costa B., Salam A., Ziegler A., et al. Memory B cells anticipate SARS-CoV-2 variants through somatic hypermutation. J Infect. 2024;88(1):57–60.</Citation><ArticleIdList><ArticleId IdType="pubmed">37913848</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankwitz K., Pallikkuth S., Sirupangi T., Kirk Kvistad D., Russel K.B., Pahwa R., et al. Compromised steady-state germinal center activity with age in nonhuman primates. Aging Cell. 2020;19(2):e13087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6996951</ArticleId><ArticleId IdType="pubmed">31840398</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton A.R., Guillaume S.M., Foster W.S., Wheatley A.K., Hill D.L., Carr E.J., et al. The memory B cell response to influenza vaccination is impaired in older persons. Cell Rep. 2022;41(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9666924</ArticleId><ArticleId IdType="pubmed">36351385</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran W.F., St Denis K.J., Hoelzemer A., Lam E.C., Nitido A.D., Sheehan M.L., et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185(3):457–66 e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8733787</ArticleId><ArticleId IdType="pubmed">34995482</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng H.F., Ackerson B.K., Luo Y., Sy L.S., Talarico C.A., Tian Y., et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022;28(5):1063–1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9117141</ArticleId><ArticleId IdType="pubmed">35189624</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsoussi W.B., Malladi S.K., Zhou J.Q., Liu Z., Ying B., Kim W., et al. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans. Nature. 2023;617(7961):592–598.</Citation><ArticleIdList><ArticleId IdType="pubmed">37011668</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortorici M.A., Addetia A., Seo A.J., Brown J., Sprouse K., Logue J., et al. Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans. Immunity. 2024;57(4):904–11 e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">38490197</ArticleId></ArticleIdList></Reference><Reference><Citation>Yisimayi A., Song W., Wang J., Jian F., Yu Y., Chen X., et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature. 2024;625(7993):148–156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10764275</ArticleId><ArticleId IdType="pubmed">37993710</ArticleId></ArticleIdList></Reference><Reference><Citation>Shawe-Taylor M., Greenwood D., Hobbs A., Dowgier G., Penn R., Sanderson T., et al. Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign. Lancet. 2024;403(10432):1133–1136.</Citation><ArticleIdList><ArticleId IdType="pubmed">38484752</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Vahokoski J., Bergen C.-R.-G., Langeland N., Cox R.J. Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection. NPJ Vaccines. 2024;9(1):37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10879087</ArticleId><ArticleId IdType="pubmed">38378953</ArticleId></ArticleIdList></Reference><Reference><Citation>Wherry E.J., Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4889009</ArticleId><ArticleId IdType="pubmed">26205583</ArticleId></ArticleIdList></Reference><Reference><Citation>Demaret J., Corroyer-Simovic B., Alidjinou E.K., Goffard A., Trauet J., Miczek S., et al. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People. Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8637126</ArticleId><ArticleId IdType="pubmed">34868051</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez Fuentes J.D., Mohamed Mohamed K., de Luna A.A., Jimenez Garcia C., Guevara-Hoyer K., Fernandez-Arquero M., et al. Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients. Front Oncol. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9808030</ArticleId><ArticleId IdType="pubmed">36605446</ArticleId></ArticleIdList></Reference><Reference><Citation>Tani Y., Takita M., Wakui M., Saito H., Nishiuchi T., Zhao T., et al. Five doses of the mRNA vaccination potentially suppress ancestral-strain stimulated SARS-CoV2-specific cellular immunity: a cohort study from the Fukushima vaccination community survey. Japan Front Immunol. 2023;14:1240425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10469480</ArticleId><ArticleId IdType="pubmed">37662950</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai C, Gao Y, Adamo S, Rivera-Ballesteros O, Hansson L, Osterborg A, et al. SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19. Sci Immunol. 2023;8(90):eadh0687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7615587</ArticleId><ArticleId IdType="pubmed">38064569</ArticleId></ArticleIdList></Reference><Reference><Citation>Joller N., Anderson A.C., Kuchroo V.K. LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation. Immunity. 2024;57(2):206–222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10919259</ArticleId><ArticleId IdType="pubmed">38354701</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J., et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245–1252.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286920</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee H., Nieves-Rosado H., Kulkarni A., Murter B., McGrath K.V., Chandran U.R., et al. Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. Cell Rep. 2021;36(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8482289</ArticleId><ArticleId IdType="pubmed">34525351</ArticleId></ArticleIdList></Reference><Reference><Citation>Brusko T.M., Wasserfall C.H., Hulme M.A., Cabrera R., Schatz D., Atkinson M.A. Influence of membrane CD25 stability on T lymphocyte activity: implications for immunoregulation. PLoS One. 2009;4(11):e7980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775921</ArticleId><ArticleId IdType="pubmed">19956753</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilber E., Martin G.E., Willberg C.B., Fox J., Nwokolo N., Fidler S., et al. Soluble plasma programmed death 1 (PD-1) and Tim-3 in primary HIV infection. AIDS. 2019;33(7):1253–1256.</Citation><ArticleIdList><ArticleId IdType="pubmed">31045943</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee H., Kane L.P. Immune regulation by Tim-3. F1000Res. 2018;7:316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5854983</ArticleId><ArticleId IdType="pubmed">29560265</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoel H., Ueland T., Hove-Skovsgaard M., Hartling H.J., Gelpi M., Benfield T., et al. Soluble T-Cell Immunoglobulin Mucin Domain-3 Is Associated With Hepatitis C Virus Coinfection and Low-Grade Inflammation During Chronic Human Immunodeficiency Virus Infection. Open Forum. Infect Dis. 2020;7(2):ofaa033</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7009472</ArticleId><ArticleId IdType="pubmed">32055642</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueland T., Heggelund L., Lind A., Holten A.R., Tonby K., Michelsen A.E., et al. Elevated plasma sTIM-3 levels in patients with severe COVID-19. J Allergy Clin Immunol. 2021;147(1):92–98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7503135</ArticleId><ArticleId IdType="pubmed">32971109</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf Y., Anderson A.C., Kuchroo V.K. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20(3):173–185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7327798</ArticleId><ArticleId IdType="pubmed">31676858</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickle R.A., DeOca K.B., Garcia B.L., Mannie M.D. Soluble CD25 imposes a low-zone IL-2 signaling environment that favors competitive outgrowth of antigen-experienced CD25(high) regulatory and memory T cells. Cell Immunol. 2023;384</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10257407</ArticleId><ArticleId IdType="pubmed">36642016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokau J., Petasch L.M., Garbers C. The soluble IL-2 receptor alpha/CD25 as a modulator of IL-2 function. Immunology. 2024;171(3):377–387.</Citation><ArticleIdList><ArticleId IdType="pubmed">38037265</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan K., Yu J., Mercado N.B., Loos C., Tostanoski L.H., Chandrashekar A., et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590(7847):630–634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7906955</ArticleId><ArticleId IdType="pubmed">33276369</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C., Ramirez S.I., Dan J.M., Grifoni A., Hastie K.M., Weiskopf D., et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020;183(4):996–1012 e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok C.K.P., Chen C., Zhao S., Sun Y., Yiu K., Chan T.O., et al. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study. Lancet Microbe. 2023;4(6):e418–e430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10115591</ArticleId><ArticleId IdType="pubmed">37086735</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemonteix J., Cohen L., Guihot A., Guerin V., Moulin C., Caseris M., et al. Comparison between enzyme-linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS-CoV-2 after symptomatic COVID-19. Immun Inflamm Dis. 2022;10(10):e617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9449588</ArticleId><ArticleId IdType="pubmed">36169252</ArticleId></ArticleIdList></Reference><Reference><Citation>Binayke A., Zaheer A., Vishwakarma S., Singh S., Sharma P., Chandwaskar R., et al. A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation. npj Vaccines. 2024;9(1):3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10762233</ArticleId><ArticleId IdType="pubmed">38167915</ArticleId></ArticleIdList></Reference><Reference><Citation>Waerlop G., Leroux-Roels G., Pagnon A., Begue S., Salaun B., Janssens M., et al. Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-ɣ Enzyme-Linked ImmunoSpot (ELISpot) protocols. J Immunol Methods. 2023;523</Citation><ArticleIdList><ArticleId IdType="pubmed">37918618</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreutmair S., Kauffmann M., Unger S., Ingelfinger F., Nunez N.G., Alberti C., et al. Preexisting comorbidities shape the immune response associated with severe COVID-19. J Allergy Clin Immunol. 2022;150(2):312–324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212690</ArticleId><ArticleId IdType="pubmed">35716951</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietz L.L., Juhl A.K., Sogaard O.S., Reekie J., Nielsen H., Johansen I.S., et al. Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity. Commun Med (Lond) 2023;3(1):58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10124939</ArticleId><ArticleId IdType="pubmed">37095240</ArticleId></ArticleIdList></Reference><Reference><Citation>Castrodeza-Sanz J., Sanz-Munoz I., Eiros J.M. Adjuvants for COVID-19 Vaccines. Vaccines (Basel) 2023;11(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10222622</ArticleId><ArticleId IdType="pubmed">37243006</ArticleId></ArticleIdList></Reference><Reference><Citation>Laing K.J., Ford E.S., Johnson M.J., Levin M.J., Koelle D.M., Weinberg A. Recruitment of naive CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity. J Clin Invest. 2023;133(23)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10688978</ArticleId><ArticleId IdType="pubmed">37788096</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>